The use of temozolomide (TMZ) for the management of aggressive pituitary tumours (APT)
has revolutionised clinical practice in this field with significantly improved clinical outcomes …

Survival for patients with aggressive pituitary tumours (APT) and pituitary carcinomas (PC)
has significantly improved following the increasing use of temozolomide (TMZ) since the first …

Temozolomide (TMZ) has been shown as an effective treatment option in aggressive
pituitary adenomas and carcinomas. This review analyses the published case series and …

Context Despite growing evidence that temozolomide (TMZ) therapy is effective for the
treatment of aggressive pituitary tumors (APTs) or carcinomas (PCs), individual therapy …

Abstract Purpose Aggressive pituitary adenomas (APAs) and pituitary carcinomas (PCs) are
challenging for their invasive nature, resistance to treatment and recurrences …

Background Treatment of aggressive pituitary adenomas typically involves a multimodality
approach based on histopathological features and may include pharmacotherapy, surgery …

Objectives Only few retrospective studies have reported an efficacy rate of temozolomide
(TMZ) in pituitary tumors (PT), all around 50%. However, the long-term survival of treated …

Temozolomide is an oral chemotherapy used to treat aggressive pituitary tumours since
2006. It is inexpensive and well tolerated, the main side effects are fatigue, nausea and …

We evaluated results of temozolomide (TMZ) therapy in six patients, aged 34–78 years,
presenting aggressive pituitary tumors. In all the patients tested O6‐methylguanine‐DNA …

Pituitary adenomas are benign intracranial neoplasms that are frequently well-controlled
with standard treatments that include surgical resection, radiotherapy, and agents that …